Breaking President Trump Signs Executive Order on Vaccine Recommendations Amidst False Claims and Expert Concerns Man Charged in Bomb Threat Against U.S. Consulate in Halifax Advocacy Groups Sue Trump Administration Over ICC Sanctions TIME Magazine Recognizes “Don’t Trust the B— in Apartment 23” as Underappreciated TV Show ‘Work in Progress’ Named Among TIME’s Most Underappreciated

Tuesday August 11, 2026

Reporter

Ascletis Pharma Inc.

5Articles Published

5Communities Covered

Published Articles

Press Release

Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35

Aug 10

Press Release

Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination

Aug 3

Press Release

Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model

Jul 27

Press Release

Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting

Jul 22

Press Release

Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30

Jul 15